Faculty of Pharmacy Newsletter:@0.147970:0.965677:0.401979:0.965677:0.401979:0.947594:0.147970:0.947594:0.011291:0.009239:0.008205:0.010274:0.005137:0.006153:0.009239:0.004620:0.009239:0.006153:0.004620:0.011291:0.010274:0.009239:0.008205:0.015393:0.009239:0.008205:0.009239:0.004620:0.013342:0.008205:0.013342:0.007188:0.005137:0.008205:0.006153:0.006153:0.008205:0.008205
46:@0.104524:0.971012:0.136879:0.971012:0.136879:0.940075:0.104524:0.940075:0.015815:0.016540
Chapter VI:@0.103809:0.063855:0.218582:0.063855:0.218582:0.040840:0.103809:0.040840:0.016980:0.013076:0.011759:0.013076:0.007832:0.010442:0.010021:0.005456:0.016980:0.009149
International Immunopharmacology:@0.260700:0.106580:0.720259:0.106580:0.720259:0.077952:0.260700:0.077952:0.011763:0.016812:0.008406:0.013426:0.011763:0.016812:0.015119:0.008406:0.008406:0.015119:0.016812:0.015119:0.008406:0.007560:0.011763:0.023525:0.023525:0.016812:0.016812:0.015119:0.015119:0.016812:0.015119:0.011763:0.023525:0.015119:0.013426:0.015119:0.008406:0.015119:0.015119:0.013426
Volume 115, February 2023, 109688:@0.339832:0.128149:0.641116:0.128149:0.641116:0.109063:0.339832:0.109063:0.011212:0.010079:0.005604:0.011208:0.015683:0.008950:0.005040:0.008959:0.010079:0.010079:0.005040:0.005040:0.013446:0.008950:0.010079:0.007842:0.011208:0.010079:0.007842:0.008950:0.005040:0.010079:0.010079:0.010079:0.010079:0.005040:0.005040:0.010079:0.010079:0.010079:0.010079:0.010079:0.010079
Marina  R.  Francis1, :@0.104762:0.226380:0.280689:0.226380:0.280689:0.207181:0.104762:0.207181:0.017921:0.008950:0.006713:0.005604:0.010079:0.008950:0.005040:0.004816:0.013446:0.005040:0.005040:0.004822:0.011208:0.006713:0.008950:0.010079:0.008950:0.005604:0.007842:0.010079:0.005040:0.005040
Ahmed R. El-Sheakh:@0.285507:0.226679:0.477156:0.226679:0.477156:0.206952:0.285507:0.206952:0.014555:0.011208:0.016792:0.008950:0.011208:0.009858:0.014555:0.005040:0.009858:0.013446:0.005604:0.006713:0.011208:0.011208:0.008950:0.010079:0.011208:0.011208
1:@0.477179:0.219983:0.483055:0.219983:0.483055:0.208483:0.477179:0.208483:0.005876
, :@0.483055:0.226380:0.493134:0.226380:0.493134:0.207181:0.483055:0.207181:0.005040:0.005040
Ghada  M.  Suddek1:@0.104762:0.243485:0.271456:0.243485:0.271456:0.224285:0.104762:0.224285:0.014555:0.010079:0.008950:0.010079:0.008950:0.005040:0.005239:0.017921:0.005040:0.005040:0.005245:0.011208:0.010079:0.010079:0.010079:0.008950:0.010079:0.010079
1:@0.104762:0.260752:0.110638:0.260752:0.110638:0.249558:0.104762:0.249558:0.005876
 Department of Pharmacology and Toxicology, :@0.110638:0.267323:0.493136:0.267323:0.493136:0.248123:0.110638:0.248123:0.005013:0.014555:0.008950:0.010079:0.008950:0.006713:0.005604:0.015683:0.008950:0.010079:0.005604:0.004995:0.010079:0.006713:0.005013:0.011208:0.010079:0.008950:0.006713:0.015683:0.008950:0.008950:0.010079:0.005592:0.010079:0.010079:0.010079:0.005011:0.008950:0.010079:0.010079:0.004647:0.010906:0.010079:0.010079:0.005604:0.008950:0.010079:0.005604:0.010079:0.010079:0.008761:0.005040:0.005040
Faculty  of  Pharmacy,  Mansoura  University, :@0.104762:0.284427:0.493136:0.284427:0.493136:0.265228:0.104762:0.265228:0.011208:0.008950:0.008950:0.010079:0.005604:0.005604:0.010079:0.005040:0.008023:0.010079:0.006713:0.005040:0.008033:0.011208:0.010079:0.008950:0.006713:0.015683:0.008950:0.008950:0.008759:0.005040:0.005040:0.008033:0.017921:0.008950:0.010079:0.007842:0.010079:0.010079:0.006713:0.008950:0.005040:0.008033:0.014555:0.010079:0.005604:0.010079:0.008950:0.006713:0.007842:0.005604:0.005604:0.008765:0.005040:0.005040
Mansoura,  Egypt.:@0.104762:0.301532:0.255212:0.301532:0.255212:0.282332:0.104762:0.282332:0.017921:0.008950:0.010079:0.007842:0.010079:0.010079:0.006713:0.008950:0.005040:0.005040:0.006558:0.012317:0.010079:0.010079:0.010079:0.005604:0.005040
Abstract:@0.104762:0.325370:0.174027:0.325370:0.174027:0.306284:0.104762:0.306284:0.013446:0.010079:0.006632:0.006632:0.007842:0.010079:0.008950:0.005604
Background::@0.104762:0.349208:0.214526:0.349208:0.214526:0.330123:0.104762:0.330123:0.013446:0.010079:0.008950:0.010079:0.010079:0.007842:0.010079:0.011208:0.011208:0.010079:0.006713
  Lipopolysaccharide  (LPS),  an :@0.214532:0.349208:0.493138:0.349208:0.493138:0.330009:0.214532:0.330009:0.005040:0.009084:0.012317:0.005604:0.010079:0.010079:0.010079:0.010079:0.005604:0.010079:0.007842:0.008950:0.008936:0.008950:0.010079:0.008950:0.006713:0.005604:0.010079:0.008950:0.005040:0.009071:0.006713:0.012317:0.011208:0.011208:0.006713:0.005040:0.005040:0.009086:0.008950:0.010079:0.005040
endotoxin  within  gram-negative  bacteria,  is :@0.104762:0.366313:0.493140:0.366313:0.493140:0.347113:0.104762:0.347113:0.008950:0.010079:0.010079:0.010079:0.005604:0.010079:0.010079:0.005604:0.010079:0.005040:0.008078:0.014555:0.005604:0.005604:0.010079:0.005604:0.010079:0.005040:0.008078:0.010079:0.006713:0.008950:0.015683:0.006713:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.010079:0.008950:0.005040:0.008070:0.010079:0.008950:0.008950:0.005604:0.008950:0.006713:0.005604:0.008950:0.005040:0.005040:0.008070:0.005604:0.007842:0.005040
associated  with  systemic  acute  inflammatory :@0.104762:0.383417:0.493148:0.383417:0.493148:0.364218:0.104762:0.364218:0.008950:0.007842:0.007842:0.010079:0.008950:0.005604:0.008950:0.005604:0.008950:0.010079:0.005040:0.005763:0.014555:0.005604:0.005604:0.010079:0.005040:0.005769:0.007842:0.010079:0.006572:0.006572:0.008950:0.015683:0.005604:0.008950:0.005040:0.005773:0.008950:0.008950:0.010079:0.005604:0.008950:0.005040:0.005763:0.005604:0.010079:0.005604:0.005604:0.008950:0.015683:0.015683:0.008950:0.005604:0.010079:0.006713:0.010079:0.005040
response after invading living tissues and results :@0.104762:0.400522:0.493146:0.400522:0.493146:0.381322:0.104762:0.381322:0.006713:0.008950:0.007842:0.010079:0.010079:0.010079:0.007842:0.008950:0.003798:0.008950:0.006713:0.005604:0.008950:0.006713:0.003798:0.005604:0.010079:0.010079:0.008950:0.010079:0.005604:0.010079:0.010079:0.003788:0.005604:0.005604:0.010079:0.005594:0.010079:0.010079:0.003798:0.005604:0.005604:0.007842:0.007842:0.010079:0.008950:0.007842:0.003798:0.008950:0.010079:0.010079:0.003796:0.006713:0.008950:0.007842:0.010079:0.005604:0.005604:0.007842:0.005040
in sepsis. The liver and kidney are both major :@0.104762:0.417626:0.493150:0.417626:0.493150:0.398426:0.104762:0.398426:0.005604:0.010079:0.006884:0.007842:0.008950:0.010079:0.007842:0.005604:0.007842:0.005040:0.006523:0.012317:0.010079:0.008950:0.006886:0.005604:0.005604:0.010079:0.008950:0.006713:0.006876:0.008950:0.010079:0.010079:0.006884:0.010079:0.005604:0.010079:0.010079:0.008950:0.010079:0.006882:0.008950:0.006713:0.008950:0.006882:0.010079:0.010079:0.005604:0.010079:0.006882:0.015683:0.008950:0.005604:0.010079:0.006713:0.005040
target organs in sepsis. Septic acute hepatic-renal :@0.104762:0.434730:0.493164:0.434730:0.493164:0.415531:0.104762:0.415531:0.005604:0.008950:0.006342:0.010079:0.008950:0.005604:0.002901:0.010079:0.006348:0.010079:0.008950:0.010079:0.007842:0.002905:0.005604:0.010079:0.002905:0.007842:0.008950:0.010079:0.007842:0.005604:0.007842:0.005040:0.002909:0.011208:0.008950:0.010079:0.005604:0.005604:0.008950:0.002899:0.008950:0.008950:0.010079:0.005604:0.008950:0.002893:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.006713:0.006713:0.008950:0.010079:0.008950:0.005604:0.005040
injury is a serious clinical condition with high :@0.104762:0.451835:0.493138:0.451835:0.493138:0.432635:0.104762:0.432635:0.005604:0.010079:0.005604:0.010079:0.006713:0.010079:0.006927:0.005604:0.007842:0.006933:0.008950:0.006929:0.007842:0.008950:0.006713:0.005604:0.010079:0.010079:0.007842:0.006933:0.008950:0.005604:0.005604:0.010079:0.005604:0.008950:0.008950:0.005604:0.006910:0.008950:0.010079:0.010079:0.010079:0.005604:0.005604:0.005604:0.010079:0.010079:0.006920:0.014555:0.005604:0.005604:0.010079:0.006929:0.010079:0.005604:0.010079:0.010079:0.005040
risk  of  morbidity  and  mortality.  Nevertheless, :@0.104762:0.468939:0.493154:0.468939:0.493154:0.449739:0.104762:0.449739:0.006713:0.005604:0.007842:0.010079:0.005040:0.003141:0.010079:0.006713:0.005040:0.003141:0.015683:0.010079:0.006713:0.010079:0.005604:0.010079:0.005604:0.005604:0.010079:0.005040:0.003135:0.008950:0.010079:0.010079:0.005040:0.003137:0.015683:0.010079:0.006713:0.005604:0.008950:0.005604:0.005604:0.005604:0.008753:0.005040:0.005040:0.003141:0.014555:0.008950:0.010079:0.008950:0.006713:0.005604:0.010079:0.008950:0.005604:0.008950:0.007842:0.007842:0.005040:0.005040
effective treatment is still lacking. :@0.104762:0.486043:0.393358:0.486043:0.393358:0.466844:0.104762:0.466844:0.008950:0.006088:0.006088:0.008950:0.008950:0.005604:0.005604:0.010079:0.008950:0.007584:0.005604:0.006713:0.008950:0.008950:0.005604:0.015683:0.008950:0.010079:0.005604:0.007580:0.005604:0.007842:0.007602:0.006572:0.006572:0.005604:0.005604:0.005604:0.007598:0.005604:0.008950:0.008950:0.010079:0.005604:0.010079:0.010079:0.005040:0.005040
Aim::@0.104762:0.509882:0.146208:0.509882:0.146208:0.490796:0.104762:0.490796:0.013446:0.005604:0.015683:0.006713
 This study highlights saroglitazar (SAR), :@0.146201:0.509882:0.493129:0.509882:0.493129:0.490682:0.146201:0.490682:0.005771:0.012317:0.010079:0.005604:0.007842:0.006134:0.006572:0.006572:0.010079:0.010079:0.010079:0.006144:0.010079:0.005604:0.010079:0.010079:0.005604:0.005604:0.010079:0.010079:0.005604:0.007842:0.006126:0.007842:0.008950:0.006713:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.008950:0.006713:0.006118:0.006713:0.011208:0.014555:0.013446:0.006713:0.005040:0.005040
a  dual  PPAR-α/γ  agonist,  as  a  proposed :@0.104762:0.526986:0.493136:0.526986:0.493136:0.507787:0.104762:0.507787:0.008950:0.005040:0.011075:0.010079:0.010079:0.008950:0.005604:0.005040:0.011071:0.011208:0.009364:0.014555:0.013446:0.006713:0.010563:0.005604:0.008910:0.005040:0.011075:0.008950:0.010079:0.010079:0.010079:0.005604:0.006572:0.006572:0.005040:0.005040:0.011077:0.008950:0.007842:0.005040:0.011077:0.008950:0.005040:0.011073:0.010079:0.006713:0.010079:0.010079:0.010079:0.007842:0.008950:0.010079:0.005040
prophylactic drug against LPS-induced hepatic-:@0.104762:0.544091:0.488110:0.544091:0.488110:0.524891:0.104762:0.524891:0.010079:0.006713:0.010079:0.010079:0.010079:0.010079:0.005604:0.008950:0.008950:0.005604:0.005604:0.008950:0.004643:0.010079:0.006713:0.010079:0.010079:0.004661:0.008950:0.010079:0.008950:0.005604:0.010079:0.006572:0.006572:0.004659:0.012317:0.011208:0.011208:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.004655:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.006713
renal  injury. :@0.104762:0.561195:0.214151:0.561195:0.214151:0.541995:0.104762:0.541995:0.006713:0.008950:0.010079:0.008950:0.005604:0.005040:0.007130:0.005604:0.010079:0.005604:0.010079:0.006713:0.008763:0.005040:0.005040
Main methods::@0.104762:0.585033:0.231026:0.585033:0.231026:0.565948:0.104762:0.565948:0.017921:0.010079:0.005604:0.011208:0.005292:0.015683:0.008950:0.005604:0.011208:0.010079:0.010079:0.007842:0.006713
 Rats were pretreated with SAR :@0.231022:0.585033:0.493129:0.585033:0.493129:0.565834:0.231022:0.565834:0.005288:0.013446:0.008950:0.005604:0.007842:0.005286:0.014555:0.008950:0.006713:0.008950:0.005284:0.010079:0.006713:0.008950:0.005604:0.006713:0.008950:0.008950:0.005604:0.008950:0.010079:0.005269:0.014555:0.005604:0.005604:0.010079:0.005286:0.011208:0.014555:0.013446:0.005040
(2 and 4 mg/kg/day) for 15 days, while sepsis :@0.104762:0.602138:0.493132:0.602138:0.493132:0.582938:0.104762:0.582938:0.006713:0.010079:0.006977:0.008950:0.010079:0.010079:0.006973:0.010079:0.006977:0.015683:0.010079:0.005604:0.010079:0.010079:0.005604:0.010079:0.008950:0.010079:0.006713:0.006963:0.006713:0.010079:0.006713:0.006977:0.010079:0.010079:0.006977:0.010079:0.008950:0.010079:0.007842:0.005040:0.006977:0.014555:0.010079:0.005604:0.005604:0.008950:0.006971:0.007842:0.008950:0.010079:0.007842:0.005604:0.007842:0.005040
was induced by LPS injection (10 mg/kg) on day :@0.104762:0.619242:0.493142:0.619242:0.493142:0.600042:0.104762:0.600042:0.014555:0.008950:0.007842:0.003550:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.003540:0.010079:0.010079:0.003548:0.012317:0.011208:0.011208:0.003548:0.005604:0.010079:0.005604:0.008950:0.008950:0.005604:0.005604:0.010059:0.010079:0.003548:0.006713:0.010079:0.010079:0.003546:0.015683:0.010079:0.005604:0.010079:0.010079:0.006713:0.003540:0.010079:0.010079:0.003546:0.010079:0.008950:0.010079:0.005040
15 one hour following SAR oral administration. :@0.104762:0.636346:0.493144:0.636346:0.493144:0.617147:0.104762:0.617147:0.010079:0.010079:0.004495:0.010079:0.010079:0.008950:0.004493:0.010079:0.010079:0.010079:0.006713:0.004497:0.006713:0.010079:0.005604:0.005604:0.010079:0.014555:0.005604:0.010079:0.010079:0.004487:0.011208:0.014555:0.013446:0.004493:0.010079:0.006713:0.008950:0.005604:0.004489:0.008950:0.010079:0.015683:0.005604:0.010079:0.005604:0.006572:0.006572:0.006713:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040:0.005040
Key  findings::@0.104762:0.660185:0.233090:0.660185:0.233090:0.641099:0.104762:0.641099:0.013446:0.008950:0.008950:0.005040:0.018000:0.005604:0.005604:0.011208:0.010079:0.005604:0.011208:0.010079:0.007842:0.006713
  SAR  pretreatment  could :@0.233099:0.660185:0.493141:0.660185:0.493141:0.640985:0.233099:0.640985:0.005040:0.018006:0.011208:0.014555:0.013446:0.005040:0.018012:0.010079:0.006713:0.008950:0.005604:0.006713:0.008950:0.008950:0.005604:0.015683:0.008950:0.010079:0.005604:0.005040:0.017982:0.008950:0.010079:0.010079:0.005604:0.010079:0.005040
successfully  mitigate  LPS-induced  hepatic-:@0.104762:0.677289:0.488110:0.677289:0.488110:0.658089:0.104762:0.658089:0.007842:0.010079:0.008950:0.008950:0.008950:0.007842:0.007842:0.006713:0.010079:0.005604:0.005604:0.010079:0.005040:0.011144:0.015683:0.005604:0.005604:0.005604:0.010079:0.008950:0.005604:0.008950:0.005040:0.011126:0.012317:0.011208:0.011208:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.005040:0.011144:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.006713
renal  injury,  evidenced  by  enhancement  of :@0.104762:0.694393:0.493134:0.694393:0.493134:0.675194:0.104762:0.675194:0.006713:0.008950:0.010079:0.008950:0.005604:0.005040:0.008184:0.005604:0.010079:0.005604:0.010079:0.006713:0.008763:0.005040:0.005040:0.008195:0.008950:0.010079:0.005604:0.010079:0.008950:0.010079:0.008950:0.008950:0.010079:0.005040:0.008178:0.010079:0.010079:0.005040:0.008195:0.008950:0.010079:0.010079:0.008950:0.010079:0.008950:0.008950:0.015683:0.008950:0.010079:0.005604:0.005040:0.008170:0.010079:0.006713:0.005040
renal and  hepatic functions and  a  decrease of :@0.104762:0.711498:0.493134:0.711498:0.493134:0.692298:0.104762:0.692298:0.006713:0.008950:0.010079:0.008950:0.005604:0.008061:0.008950:0.010079:0.010079:0.005040:0.003028:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.008053:0.006713:0.010079:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.007842:0.008063:0.008950:0.010079:0.010079:0.005040:0.003028:0.008950:0.005040:0.003028:0.010079:0.008950:0.008950:0.006713:0.008950:0.008950:0.007842:0.008950:0.008057:0.010079:0.006713:0.005040
tissue  pathological  injury.  Meanwhile,  SAR :@0.104762:0.728602:0.493128:0.728602:0.493128:0.709403:0.104762:0.709403:0.005604:0.005604:0.007842:0.007842:0.010079:0.008950:0.005040:0.007695:0.010079:0.008950:0.005604:0.010079:0.010079:0.005594:0.010079:0.010079:0.005604:0.008950:0.008950:0.005604:0.005040:0.007685:0.005604:0.010079:0.005604:0.010079:0.006713:0.008765:0.005040:0.005040:0.007697:0.017921:0.008950:0.008950:0.010079:0.014555:0.010079:0.005604:0.005604:0.008950:0.005040:0.005040:0.007689:0.011208:0.014555:0.013446:0.005040
alleviated  LPS-induced  oxidative  stress;  it :@0.104762:0.745707:0.493142:0.745707:0.493142:0.726507:0.104762:0.726507:0.008950:0.005604:0.005604:0.008950:0.010079:0.005604:0.008950:0.005604:0.008950:0.010079:0.005040:0.010785:0.012317:0.011208:0.011208:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.005040:0.010805:0.010079:0.010079:0.005604:0.010079:0.008950:0.005604:0.005604:0.010079:0.008950:0.005040:0.010793:0.006572:0.006572:0.006713:0.008950:0.007842:0.007842:0.005604:0.005040:0.010819:0.005604:0.005604:0.005040
reduced  malondialdehyde  (MDA)  levels  and :@0.104762:0.762811:0.493138:0.762811:0.493138:0.743611:0.104762:0.743611:0.006713:0.008950:0.010079:0.010079:0.008950:0.008950:0.010079:0.005040:0.005981:0.015683:0.008950:0.005604:0.010069:0.010079:0.010079:0.005604:0.008950:0.005604:0.010079:0.008950:0.010079:0.010079:0.010079:0.008950:0.005040:0.005975:0.006713:0.017921:0.014555:0.014555:0.006713:0.005040:0.005999:0.005604:0.008950:0.010079:0.008950:0.005604:0.007842:0.005040:0.005981:0.008950:0.010079:0.010079:0.005040
ameliorated  decreased  levels  of  superoxide :@0.104762:0.779915:0.493148:0.779915:0.493148:0.760716:0.104762:0.760716:0.008950:0.015683:0.008950:0.005604:0.005604:0.010079:0.006713:0.008950:0.005604:0.008950:0.010079:0.005040:0.009053:0.010079:0.008950:0.008950:0.006713:0.008950:0.008950:0.007842:0.008950:0.010079:0.005040:0.009065:0.005604:0.008950:0.010079:0.008950:0.005604:0.007842:0.005040:0.009075:0.010079:0.006713:0.005040:0.009079:0.007842:0.010079:0.010079:0.008950:0.006713:0.010079:0.010079:0.005604:0.010079:0.008950:0.005040
dismutase (SOD) and glutathione (GSH). LPS-:@0.104762:0.797020:0.488092:0.797020:0.488092:0.777820:0.104762:0.777820:0.010079:0.005604:0.007842:0.015683:0.010079:0.005604:0.008950:0.007842:0.008950:0.005771:0.006713:0.011208:0.014555:0.014555:0.006713:0.005794:0.008950:0.010079:0.010079:0.005780:0.010079:0.005604:0.010079:0.005604:0.008950:0.005604:0.010079:0.005604:0.010079:0.010079:0.008950:0.005761:0.006713:0.014555:0.011208:0.014555:0.006713:0.005040:0.005794:0.012317:0.011208:0.011208:0.006713
induced elevations in hepatic and renal nuclear :@0.104762:0.814124:0.493154:0.814124:0.493154:0.794924:0.104762:0.794924:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.005858:0.008950:0.005604:0.008950:0.010079:0.008936:0.005604:0.005604:0.010079:0.010079:0.007842:0.005864:0.005604:0.010079:0.005864:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.005856:0.008950:0.010079:0.010079:0.005864:0.006713:0.008950:0.010079:0.008950:0.005604:0.005858:0.010079:0.010079:0.008950:0.005604:0.008950:0.008950:0.006713:0.005040
factor-kappa  B  (NF-κB),  phosphorylated :@0.104762:0.831228:0.493140:0.831228:0.493140:0.812029:0.104762:0.812029:0.006713:0.008950:0.008950:0.005604:0.010079:0.006300:0.006713:0.010079:0.008950:0.010079:0.010079:0.008950:0.005040:0.018157:0.013446:0.005040:0.018161:0.006713:0.014555:0.011208:0.006713:0.010160:0.013446:0.006713:0.005040:0.005040:0.018161:0.010079:0.010079:0.010079:0.007842:0.010079:0.010079:0.010079:0.006713:0.010079:0.005604:0.008950:0.005604:0.008950:0.010079:0.005040
inhibitor of kappa B alpha (p-IκBα), interferon-:@0.104762:0.848333:0.488112:0.848333:0.488112:0.829133:0.104762:0.829133:0.005604:0.010079:0.010079:0.005604:0.010079:0.005604:0.005604:0.010079:0.006713:0.004913:0.010079:0.006713:0.004925:0.010079:0.008950:0.010079:0.010079:0.008950:0.004923:0.013446:0.004925:0.008950:0.005604:0.010079:0.010079:0.008950:0.004917:0.006713:0.010079:0.006713:0.006713:0.010160:0.013446:0.010563:0.006713:0.005040:0.004923:0.005604:0.010079:0.005604:0.008950:0.006713:0.006713:0.008950:0.006713:0.010079:0.010079:0.006713
beta (IFN-β), and hepatic high mobility group :@0.104762:0.865437:0.493132:0.865437:0.493132:0.846238:0.104762:0.846238:0.010079:0.008950:0.005604:0.008950:0.007215:0.006713:0.006713:0.011208:0.014555:0.006713:0.010261:0.006713:0.005040:0.007223:0.008950:0.010079:0.010079:0.007221:0.010079:0.008950:0.010079:0.008950:0.005604:0.005604:0.008950:0.007209:0.010079:0.005604:0.010079:0.010079:0.007219:0.015683:0.010079:0.010079:0.005604:0.005604:0.005604:0.005604:0.010079:0.007207:0.010079:0.006713:0.010079:0.010079:0.010079:0.005040
box-1  (HMGB-1)  contents  were  significantly :@0.104762:0.882542:0.493138:0.882542:0.493138:0.863342:0.104762:0.863342:0.010079:0.010079:0.010079:0.006713:0.010079:0.005040:0.004856:0.006713:0.014555:0.017921:0.014555:0.013446:0.006713:0.010079:0.006713:0.005040:0.004856:0.008950:0.010079:0.010079:0.005604:0.008950:0.010079:0.005590:0.007842:0.005040:0.004860:0.014555:0.008950:0.006713:0.008950:0.005040:0.004852:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.005604:0.010079:0.005040
attenuated in SAR-treated groups. SAR showed :@0.104762:0.899646:0.493132:0.899646:0.493132:0.880446:0.104762:0.880446:0.008950:0.005604:0.005604:0.008950:0.010079:0.010079:0.008950:0.005604:0.008950:0.010079:0.004645:0.005604:0.010079:0.004665:0.011208:0.014555:0.013446:0.006713:0.005604:0.006713:0.008950:0.008950:0.005604:0.008950:0.010079:0.004661:0.010079:0.006713:0.010079:0.010079:0.010079:0.007842:0.005040:0.004671:0.011208:0.014555:0.013446:0.004675:0.007842:0.010079:0.010079:0.014555:0.008950:0.010079:0.005040
an  advantageous  impact  against  LPS-induced :@0.104762:0.916750:0.493142:0.916750:0.493142:0.897551:0.104762:0.897551:0.008950:0.010079:0.005040:0.004374:0.008950:0.010079:0.010079:0.008950:0.010079:0.005604:0.008950:0.010079:0.008936:0.010079:0.010079:0.007842:0.005040:0.004380:0.005604:0.015683:0.010079:0.008950:0.008950:0.005604:0.005040:0.004362:0.008950:0.010079:0.008950:0.005604:0.010079:0.006572:0.006572:0.005040:0.004376:0.012317:0.011208:0.011208:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.005040
Saroglitazar, a dual PPAR-α/γ agonist, alleviates LPS-induced :@0.112803:0.169937:0.894802:0.169937:0.894802:0.141308:0.112803:0.141308:0.016812:0.015119:0.011763:0.015119:0.015119:0.008406:0.008406:0.008406:0.015119:0.011763:0.015119:0.010096:0.007560:0.007560:0.015119:0.007560:0.015119:0.016812:0.015119:0.008406:0.007560:0.018475:0.016223:0.020169:0.020169:0.010069:0.016722:0.008406:0.012579:0.007560:0.015119:0.015119:0.015119:0.016812:0.008406:0.009948:0.009948:0.007560:0.007560:0.015119:0.008406:0.008406:0.013426:0.013426:0.008406:0.015119:0.008406:0.013426:0.011763:0.007560:0.018475:0.018475:0.016812:0.010069:0.008406:0.016812:0.015119:0.016812:0.013426:0.013426:0.015119:0.007560
hepatic and renal injury in rats:@0.305512:0.193693:0.694494:0.193693:0.694494:0.165064:0.305512:0.165064:0.016812:0.013426:0.015119:0.015119:0.008406:0.008406:0.013426:0.007560:0.015119:0.016812:0.015119:0.007560:0.011763:0.013426:0.016812:0.015119:0.008406:0.007560:0.008406:0.016812:0.008406:0.016812:0.011763:0.013426:0.007560:0.008406:0.016812:0.007560:0.011763:0.015119:0.008406:0.011763
activation  of  non-canonical  inflammasome :@0.511904:0.536144:0.900294:0.536144:0.900294:0.516945:0.511904:0.516945:0.008950:0.008950:0.005604:0.005604:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040:0.012998:0.010079:0.006713:0.005040:0.013018:0.010079:0.010079:0.010079:0.006713:0.008950:0.008950:0.010079:0.010079:0.010079:0.005604:0.008950:0.008950:0.005604:0.005040:0.013002:0.005604:0.010079:0.005604:0.005604:0.008950:0.015683:0.015683:0.008950:0.007842:0.010079:0.015683:0.008950:0.005040
and  pyroptosis  via  a  significant  reduction :@0.511904:0.553249:0.900290:0.553249:0.900290:0.534049:0.511904:0.534049:0.008950:0.010079:0.010079:0.005040:0.010265:0.010079:0.010079:0.006713:0.010079:0.010079:0.005604:0.010079:0.007842:0.005604:0.007842:0.005040:0.010265:0.010079:0.005604:0.008950:0.005040:0.010261:0.008950:0.005040:0.010265:0.007842:0.005604:0.010079:0.010079:0.005604:0.005604:0.005604:0.008950:0.008950:0.010079:0.005604:0.005040:0.010257:0.006713:0.008950:0.010079:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040
in  cysteinyl  aspartate-specific  proteinase-11 :@0.511904:0.570353:0.900278:0.570353:0.900278:0.551153:0.511904:0.551153:0.005604:0.010079:0.005040:0.010386:0.008950:0.010079:0.006572:0.006572:0.008950:0.005604:0.010079:0.010079:0.005604:0.005040:0.010382:0.008950:0.007842:0.010079:0.008950:0.006713:0.005604:0.008950:0.005604:0.008950:0.006713:0.007842:0.010067:0.008950:0.008950:0.005604:0.005604:0.005604:0.008950:0.005040:0.010380:0.010079:0.006713:0.010079:0.005604:0.008950:0.005604:0.010079:0.008950:0.007842:0.008950:0.006713:0.009319:0.010079:0.005040
(Caspase-11)  and  gasdermin  D  (GSDMD) :@0.511904:0.587458:0.900260:0.587458:0.900260:0.568258:0.511904:0.568258:0.006713:0.013446:0.008950:0.007842:0.010079:0.008950:0.007842:0.008950:0.006713:0.009329:0.010079:0.006713:0.005040:0.010924:0.008950:0.010079:0.010079:0.005040:0.010920:0.010079:0.008950:0.007842:0.010079:0.008950:0.006713:0.015683:0.005604:0.010079:0.005040:0.010916:0.014555:0.005040:0.010926:0.006713:0.014555:0.011208:0.014555:0.017921:0.014555:0.006713:0.005040
expressions.  Moreover,  Nucleotide-Binding :@0.511904:0.604562:0.900300:0.604562:0.900300:0.585362:0.511904:0.585362:0.008950:0.010079:0.010079:0.006713:0.008950:0.007842:0.007842:0.005604:0.010079:0.010079:0.007842:0.005040:0.005040:0.015159:0.017921:0.010079:0.006713:0.008950:0.010079:0.010079:0.008950:0.005904:0.005040:0.005040:0.015159:0.014555:0.010079:0.008950:0.005604:0.008950:0.010079:0.005604:0.005604:0.010079:0.008950:0.006713:0.013446:0.005604:0.010079:0.010079:0.005604:0.010079:0.010079:0.005040
Oligomerization Domain (NOD)-Like Receptor :@0.511904:0.621666:0.900286:0.621666:0.900286:0.602467:0.511904:0.602467:0.014555:0.005604:0.005604:0.010079:0.010079:0.015683:0.008950:0.006713:0.005604:0.008950:0.008950:0.005604:0.005604:0.010079:0.010079:0.004227:0.014555:0.010079:0.015683:0.008950:0.005604:0.010079:0.004245:0.006713:0.014555:0.014555:0.014555:0.006713:0.006713:0.012317:0.005604:0.010079:0.008950:0.004251:0.013446:0.008950:0.008950:0.008950:0.010079:0.005604:0.010079:0.006713:0.005040
Protein  3  (NLRP3)  inflammasome  activation :@0.511904:0.638771:0.900300:0.638771:0.900300:0.619571:0.511904:0.619571:0.011208:0.006713:0.010079:0.005604:0.008950:0.005604:0.010079:0.005040:0.005405:0.010079:0.005040:0.005413:0.006713:0.014555:0.012317:0.013446:0.011208:0.010079:0.006713:0.005040:0.005415:0.005604:0.010079:0.005604:0.005604:0.008950:0.015683:0.015683:0.008950:0.007842:0.010079:0.015683:0.008950:0.005040:0.005396:0.008950:0.008950:0.005604:0.005604:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.005040
with concomitant expression and activation of :@0.511904:0.655875:0.900280:0.655875:0.900280:0.636675:0.511904:0.636675:0.014555:0.005604:0.005604:0.010079:0.007247:0.008950:0.010079:0.010079:0.008950:0.010079:0.015683:0.005592:0.005604:0.008950:0.010079:0.005604:0.007241:0.008950:0.010079:0.010079:0.006713:0.008950:0.007842:0.007842:0.005604:0.010079:0.010079:0.007251:0.008950:0.010079:0.010079:0.007249:0.008950:0.008950:0.005604:0.005604:0.010079:0.008950:0.005604:0.005604:0.010079:0.010079:0.007227:0.010079:0.006713:0.005040
caspase-1 and release of interleukin-1beta (IL-:@0.511904:0.672979:0.895245:0.672979:0.895245:0.653780:0.511904:0.653780:0.008950:0.008950:0.007842:0.010079:0.008950:0.007842:0.008950:0.006713:0.010079:0.006592:0.008950:0.010079:0.010079:0.006598:0.006713:0.008950:0.005604:0.008950:0.008950:0.007842:0.008950:0.006586:0.010079:0.006713:0.006596:0.005604:0.010079:0.005604:0.008950:0.006713:0.005604:0.008950:0.010079:0.010079:0.005604:0.010079:0.006713:0.010079:0.010079:0.008950:0.005604:0.008950:0.006570:0.006713:0.006713:0.012317:0.006713
1β)  were  considerably  diminished  following :@0.511904:0.690084:0.900288:0.690084:0.900288:0.670884:0.511904:0.670884:0.010079:0.010261:0.006713:0.005040:0.006491:0.014555:0.008950:0.006713:0.008950:0.005040:0.006491:0.008950:0.010079:0.010079:0.007842:0.005604:0.010079:0.008950:0.006713:0.008950:0.010079:0.005604:0.010079:0.005040:0.006483:0.010079:0.005604:0.015683:0.005604:0.010079:0.005604:0.007842:0.010079:0.008950:0.010079:0.005040:0.006485:0.006713:0.010079:0.005604:0.005604:0.010079:0.014555:0.005604:0.010079:0.010079:0.005040
SAR  pretreatment. :@0.511904:0.707188:0.679502:0.707188:0.679502:0.687989:0.511904:0.687989:0.011208:0.014555:0.013446:0.005040:0.011388:0.010079:0.006713:0.008950:0.005604:0.006713:0.008950:0.008950:0.005604:0.015683:0.008950:0.010079:0.005604:0.005040:0.005040
Significance::@0.511904:0.731026:0.621669:0.731026:0.621669:0.711941:0.511904:0.711941:0.011208:0.005604:0.010079:0.011208:0.005604:0.005604:0.005604:0.008950:0.010079:0.011208:0.008950:0.008950:0.006713
  SAR  could  be  considered  a :@0.621665:0.731026:0.900287:0.731026:0.900287:0.711827:0.621665:0.711827:0.005040:0.009815:0.011208:0.014555:0.013446:0.005040:0.009823:0.008950:0.010079:0.010079:0.005604:0.010079:0.005040:0.009815:0.010079:0.008950:0.005040:0.009813:0.008950:0.010079:0.010079:0.007842:0.005604:0.010079:0.008950:0.006713:0.008950:0.010079:0.005040:0.009807:0.008950:0.005040
prophylactic  anti-inflammatory  antioxidant :@0.511904:0.748131:0.900296:0.748131:0.900296:0.728931:0.511904:0.728931:0.010079:0.006713:0.010079:0.010079:0.010079:0.010079:0.005604:0.008950:0.008950:0.005604:0.005604:0.008950:0.005040:0.018103:0.008950:0.010079:0.005604:0.005604:0.006713:0.005604:0.010079:0.005604:0.005604:0.008950:0.015683:0.015665:0.008950:0.005604:0.010079:0.006713:0.010079:0.005040:0.018115:0.008950:0.010079:0.005604:0.005604:0.010079:0.010079:0.005604:0.010079:0.008950:0.010079:0.005604:0.005040
drug  against  LPS-induced  liver  and  kidney :@0.511904:0.765235:0.900290:0.765235:0.900290:0.746036:0.511904:0.746036:0.010079:0.006713:0.010079:0.010079:0.005040:0.007640:0.008950:0.010079:0.008950:0.005604:0.010079:0.006572:0.006572:0.005040:0.007638:0.012317:0.011208:0.011208:0.006713:0.005604:0.010079:0.010079:0.010079:0.008950:0.008950:0.010079:0.005040:0.007642:0.005604:0.005604:0.010079:0.008950:0.006713:0.005040:0.007630:0.008950:0.010079:0.010079:0.005040:0.007638:0.010079:0.005604:0.010079:0.010079:0.008950:0.010079:0.005040
injury. :@0.511904:0.782340:0.575118:0.782340:0.575118:0.763140:0.511904:0.763140:0.006652:0.011128:0.006652:0.011128:0.007761:0.009813:0.005040:0.005040
https://doi.org/10.1016/j.intimp.2023.109688 :@0.511904:0.806178:0.881154:0.806178:0.881154:0.786978:0.511904:0.786978:0.010079:0.005604:0.005604:0.010079:0.007842:0.005604:0.005604:0.005604:0.010079:0.010079:0.005604:0.005040:0.010079:0.006332:0.010079:0.005604:0.010079:0.010079:0.005040:0.010079:0.010079:0.010079:0.010079:0.005604:0.005604:0.005040:0.005604:0.010079:0.005604:0.005604:0.015683:0.010079:0.005040:0.010079:0.010079:0.010079:0.010079:0.005040:0.010079:0.010079:0.010079:0.010079:0.010079:0.010079:0.005040